<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39203953</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">827</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12080827</ELocationID><Abstract><AbstractText><b>Background</b>: Protein-based pneumococcal vaccines (PBPVs) may offer expanded protection against <i>Streptococcus pneumoniae</i> and tackle the antimicrobial resistance crisis in pneumococcal infections. This study examined the safety and immunogenicity in healthy adults vaccinated with three doses of a protein-based pneumococcal vaccine containing pneumococcal surface protein A (PspA) (PRX1, P3296 and P5668) and in combination with a recombinant detoxified pneumolysin protein (PlyLD). <b>Methods</b>: This phase Ia randomized, double blind, placebo-controlled clinical study enrolled healthy adults aged 18-49 years. The participants were randomized into experimental (low-dose, medium-dose, high-dose) and placebo groups in a ratio of 3:1. Three doses of investigational vaccine were given to the participants with an interval of two months. Safety endpoints included the occurrence of total adverse reactions, solicited local and systemic adverse reactions, unsolicited adverse reactions, serious adverse events (SAEs), and several laboratory parameters. Immunogenicity endpoints included geometric mean titers (GMT) of anti-PspA (PRX1, P3296 and P5668) and anti-PlyLD antibodies level as determined by ELISA, seropositivity rates of PspA and PlyLD antibodies (&gt;4-fold increase) and neutralization activity of anti-Ply antibody in serum. <b>Results</b>: A total of 118 participants completed the study of three doses. The candidate PBPV was safe and well-tolerated in all experimental groups. No vaccine-related SAEs were observed in this study. Most solicited adverse reactions were mild and transient. The most frequently reported solicited adverse reactions in the medium- and high-dose groups was pain at the injection site, while in the low-dose group it was elevated blood pressure. The immunogenicity data showed a sharp increase in the GMT level of anti-PspA-RX1, anti-PspA-3296, anti-PspA-5668, and anti-PlyLD antibodies in serum. The results also showed that the elicited antibodies were dosage-dependent. The high-dose group showed a higher immune response against PspA-RX1, PspA-3296, PspA-5668, and PlyLD antigens. However, repeat vaccination did not increase the level of anti-PspA antibodies but the level of anti-PlyLD antibody. High seropositivity rates were also observed for anti-PspA-RX1, anti-PspA-3296, anti-PspA-5668, and anti-PlyLD antibodies. In addition, a significant difference in the GMT levels of anti-Ply antibody between the high-, medium-, and low-dose groups post each vaccination were indicated by neutralization activity tests. <b>Conclusions</b>: The PBPV showed a safe and immunogenic profile in this clinical trial. Taking into consideration both safety and immunogenicity data, we propose a single dose of 50 µg (medium dose) of PBPV as the optimum approach in providing expanded protection against <i>Streptococcus pneumoniae</i>.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gou</LastName><ForeName>Jinbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Wangyang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruijie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yongli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Feiyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CanSino Biologics Inc., Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Dongyang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LHGJ20210135</GrantID><Agency>construction project of medical technology research and development plan of Henan province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">pneumococcal surface protein A</Keyword><Keyword MajorTopicYN="N">pneumolysin protein</Keyword><Keyword MajorTopicYN="N">protein-based pneumococcal vaccine</Keyword></KeywordList><CoiStatement>X.W., J.G., H.H., R.W., F.W. and T.Z. are employees of CanSino Biologics. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39203953</ArticleId><ArticleId IdType="pmc">PMC11358999</ArticleId><ArticleId IdType="doi">10.3390/vaccines12080827</ArticleId><ArticleId IdType="pii">vaccines12080827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiser J.N., Ferreira D.M., Paton J.C. Streptococcus pneumoniae: Transmission, colonization and invasion. Nat. Rev. Microbiol. 2018;16:355–367. doi: 10.1038/s41579-018-0001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0001-8</ArticleId><ArticleId IdType="pmc">PMC5949087</ArticleId><ArticleId IdType="pubmed">29599457</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimura A., Hamaguchi S., Akeda Y., Tomono K. Mechanisms Underlying Pneumococcal Transmission and Factors Influencing Host-Pneumococcus Interaction: A Review. Front. Cell. Infect. Microbiol. 2021;11:639450. doi: 10.3389/fcimb.2021.639450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.639450</ArticleId><ArticleId IdType="pmc">PMC8113816</ArticleId><ArticleId IdType="pubmed">33996623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganaie F., Maruhn K., Li C., Porambo R.J., Elverdal P.L., Abeygunwardana C., van der Linden M., Duus J., Sheppard C.L., Nahm M.H. Structural, Genetic, and Serological Elucidation of Streptococcus pneumoniae Serogroup 24 Serotypes: Discovery of a New Serotype, 24C, with a Variable Capsule Structure. J. Clin. Microbiol. 2021;59:e0054021. doi: 10.1128/JCM.00540-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00540-21</ArticleId><ArticleId IdType="pmc">PMC8218768</ArticleId><ArticleId IdType="pubmed">33883183</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. 2017.  [(accessed on 1 November 2023)].  Available online:  https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.</Citation></Reference><Reference><Citation>Kim S.H., Bae I.K., Park D., Lee K., Kim N.Y., Song S.A., Kim H.R., Jeon G.W., Urm S.-H., Shin J.H. Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Isolates Causing Invasive and Noninvasive Pneumococcal Diseases in Korea from 2008 to 2014. BioMed Res. Int. 2016;2016:6950482. doi: 10.1155/2016/6950482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6950482</ArticleId><ArticleId IdType="pmc">PMC4904076</ArticleId><ArticleId IdType="pubmed">27314035</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen L., Taylor R.J., Young-Xu Y., Haber M., May L., Klugman K.P. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio. 2011;2:e00309–e00310. doi: 10.1128/mBio.00309-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00309-10</ArticleId><ArticleId IdType="pmc">PMC3025524</ArticleId><ArticleId IdType="pubmed">21264063</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Dhoubhadel B.G., Ishifuji T., Yasunami M., Yaegashi M., Asoh N., Ishida M., Hamaguchi S., Aoshima M., Ariyoshi K., et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: A multicentre, prospective, test-negative design study. Lancet Infect. Dis. 2017;17:313–321. doi: 10.1016/S1473-3099(17)30049-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30049-X</ArticleId><ArticleId IdType="pubmed">28126327</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian K., Henriques-Normark B., Normark S. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: From nasopharyngeal colonizer to intracellular pathogen. Cell. Microbiol. 2019;21:e13077. doi: 10.1111/cmi.13077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.13077</ArticleId><ArticleId IdType="pmc">PMC6899785</ArticleId><ArticleId IdType="pubmed">31251447</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott N.R., Mann B., Tuomanen E.I., Orihuela C.J. Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines. Vaccines. 2021;9:209. doi: 10.3390/vaccines9030209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030209</ArticleId><ArticleId IdType="pmc">PMC8002124</ArticleId><ArticleId IdType="pubmed">33801372</ArticleId></ArticleIdList></Reference><Reference><Citation>Defrance T., Taillardet M., Genestier L. T cell-independent B cell memory. Curr. Opin. Immunol. 2011;23:330–336. doi: 10.1016/j.coi.2011.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.03.004</ArticleId><ArticleId IdType="pubmed">21482090</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsells E., Guillot L., Nair H., Kyaw M.H. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0177113. doi: 10.1371/journal.pone.0177113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177113</ArticleId><ArticleId IdType="pmc">PMC5423631</ArticleId><ArticleId IdType="pubmed">28486544</ArticleId></ArticleIdList></Reference><Reference><Citation>Masomian M., Ahmad Z., Gew L.T., Poh C.L. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines. 2020;8:132. doi: 10.3390/vaccines8010132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8010132</ArticleId><ArticleId IdType="pmc">PMC7157650</ArticleId><ArticleId IdType="pubmed">32192117</ArticleId></ArticleIdList></Reference><Reference><Citation>Entwisle C., Hill S., Pang Y., Joachim M., McIlgorm A., Colaco C., Goldblatt D., D’Argoeuves P.D.G., Bailey C. Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. Vaccine. 2017;35:7181–7186. doi: 10.1016/j.vaccine.2017.10.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.10.076</ArticleId><ArticleId IdType="pubmed">29132988</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks W.A., Chang L.-J., Sheng X., Hopfer R. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015;33:4610–4617. doi: 10.1016/j.vaccine.2015.06.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.078</ArticleId><ArticleId IdType="pubmed">26143615</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutola A., Ota M., Ogundare E., Antonio M., Owiafe P., Worwui A., Greenwood B., Alderson M., Traskine M., Verlant V., et al. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2–4 years: A phase II randomized study. Hum. Vaccines Immunother. 2016;12:393–402. doi: 10.1080/21645515.2015.1111496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1111496</ArticleId><ArticleId IdType="pmc">PMC5049746</ArticleId><ArticleId IdType="pubmed">26618243</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels G., Maes C., De Boever F., Traskine M., Rüggeberg J.U., Borys D. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine. 2014;32:6838–6846. doi: 10.1016/j.vaccine.2014.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.02.052</ArticleId><ArticleId IdType="pubmed">24607003</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutola A., Ota M.O.C., Antonio M., Ogundare E.O., Saidu Y., Foster-Nyarko E., Owiafe P.K., Ceesay F., Worwui A., Idoko O.T., et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study. Vaccine. 2017;35:2531–2542. doi: 10.1016/j.vaccine.2017.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.071</ArticleId><ArticleId IdType="pubmed">28389097</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfroid F., Hermand P., Verlant V., Denoël P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect. Immun. 2011;79:238–245. doi: 10.1128/IAI.00378-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00378-10</ArticleId><ArticleId IdType="pmc">PMC3019885</ArticleId><ArticleId IdType="pubmed">20956575</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiberling M., Bologa M., Brookes R., Ochs M., Go K., Neveu D., Kamtchoua T., Lashley P., Yuan T., Gurunathan S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012;30:7455–7460. doi: 10.1016/j.vaccine.2012.10.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.080</ArticleId><ArticleId IdType="pubmed">23131206</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichichero M.E. Pneumococcal whole-cell and protein-based vaccines: Changing the paradigm. Expert Rev. Vaccines. 2017;16:1181–1190. doi: 10.1080/14760584.2017.1393335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1393335</ArticleId><ArticleId IdType="pmc">PMC6277969</ArticleId><ArticleId IdType="pubmed">29130395</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi N., Esposito S. Development of pneumococcal vaccines over the last 10 years. Expert Opin. Biol. Ther. 2018;18:7–17. doi: 10.1080/14712598.2018.1384462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2018.1384462</ArticleId><ArticleId IdType="pubmed">29022363</ArticleId></ArticleIdList></Reference><Reference><Citation>Briles D.E., Paton J.C., Mukerji R., Swiatlo E., Crain M.J. Pneumococcal Vaccines. Microbiol Spectr. 2019;7:10-1128. doi: 10.1128/microbiolspec.GPP3-0028-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.GPP3-0028-2018</ArticleId><ArticleId IdType="pmc">PMC10921951</ArticleId><ArticleId IdType="pubmed">31858954</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagousi T., Basdeki P., Routsias J., Spoulou V. Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens. Vaccines. 2019;7:9. doi: 10.3390/vaccines7010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7010009</ArticleId><ArticleId IdType="pmc">PMC6466302</ArticleId><ArticleId IdType="pubmed">30669439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadioglu A., Coward W., Colston M.J., Hewitt C.R.A., Andrew P.W. CD4-T-Lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 2004;72:2689–2697. doi: 10.1128/IAI.72.5.2689-2697.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.5.2689-2697.2004</ArticleId><ArticleId IdType="pmc">PMC387852</ArticleId><ArticleId IdType="pubmed">15102777</ArticleId></ArticleIdList></Reference><Reference><Citation>Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., Kurt-Jones E., Paton J.C., Wessels M.R., Golenbock D.T. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA. 2003;100:1966–1971. doi: 10.1073/pnas.0435928100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0435928100</ArticleId><ArticleId IdType="pmc">PMC149942</ArticleId><ArticleId IdType="pubmed">12569171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill S., Entwisle C., Pang Y., Joachim M., McIlgorm A., Dalton K., Burbidge P., Colaco C., Brown J., Goldblatt D., et al. Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae. Vaccine. 2018;36:4255–4264. doi: 10.1016/j.vaccine.2018.05.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.122</ArticleId><ArticleId IdType="pubmed">29895498</ArticleId></ArticleIdList></Reference><Reference><Citation>Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., Virolainen A., Swiatlo E., Hollingshead S.K. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 2000;68:796–800. doi: 10.1128/IAI.68.2.796-800.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.68.2.796-800.2000</ArticleId><ArticleId IdType="pmc">PMC97207</ArticleId><ArticleId IdType="pubmed">10639448</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno A.T., Oliveira M.L.S., Ferreira D.M., Ho P.L., Darrieux M., Leite L.C.C., Ferreira J.M.C., Jr., Pimenta F.C., Andrade A.L.S.S., Miyaji E.N. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin. Vaccine Immunol. 2010;17:439–446. doi: 10.1128/CVI.00430-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00430-09</ArticleId><ArticleId IdType="pmc">PMC2837969</ArticleId><ArticleId IdType="pubmed">20089795</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira M.L.S., Miyaji E.N., Ferreira D.M., Moreno A.T., Ferreira P.C.D., Lima F.A., Santos F.L., Sakauchi M.A., Takata C.S., Higashi H.G., et al. Combination of pneumococcal surface protein A (PspA) with Whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE. 2010;5:e10863. doi: 10.1371/journal.pone.0010863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010863</ArticleId><ArticleId IdType="pmc">PMC2877721</ArticleId><ArticleId IdType="pubmed">20523738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong I.G., Sato A., Yuki Y., Nochi T., Takahashi H., Sawada S., Mejima M., Kurokawa S., Okada K., Sato S., et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect. Immun. 2013;81:1625–1634. doi: 10.1128/IAI.00240-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00240-13</ArticleId><ArticleId IdType="pmc">PMC3647999</ArticleId><ArticleId IdType="pubmed">23460513</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano H., Kawabata M., Sugita G., Tsuruhara A., Ohori J., Jimura T., Miyashita K., Kurono Y., Tomonaga K., Briles D.E., et al. Transcutaneous immunization with pneumococcal surface protein A in mice. Laryngoscope. 2018;128:E91–E96. doi: 10.1002/lary.26971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.26971</ArticleId><ArticleId IdType="pubmed">29226330</ArticleId></ArticleIdList></Reference><Reference><Citation>National Medical Products Administration  Good Manufacturing Practice for Drugs.  [(accessed on 1 July 2024)];2019  Available online:  https://english.nmpa.gov.cn/2019-07/25/c_390613.htm.</Citation></Reference><Reference><Citation>Hollingshead S.K., Becker R., Briles D.E. Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 2000;68:5889–5900. doi: 10.1128/IAI.68.10.5889-5900.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.68.10.5889-5900.2000</ArticleId><ArticleId IdType="pmc">PMC101551</ArticleId><ArticleId IdType="pubmed">10992499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukerji R., Hendrickson C., Genschmer K.R., Park S.-S., Bouchet V., Goldstein R., Lefkowitz E.J., Briles D.E. The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine. Vaccine. 2018;36:6834–6843. doi: 10.1016/j.vaccine.2018.08.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.08.045</ArticleId><ArticleId IdType="pmc">PMC6366627</ArticleId><ArticleId IdType="pubmed">30293761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vela Coral M.C., Fonseca N., Castañeda E., Di Fabio J.L., Hollingshead S.K., Briles D.E. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg. Infect. Dis. 2001;7:832–836. doi: 10.3201/eid0705.017510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0705.017510</ArticleId><ArticleId IdType="pmc">PMC2631885</ArticleId><ArticleId IdType="pubmed">11747695</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandileone M.C.C., Andrade A.L.S., Teles E.M., Zanella R.C., Yara T.I., Di Fabio J.L., Hollingshead S.K. Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: Towards novel pneumococcal protein vaccines. Vaccine. 2004;22:3890–3896. doi: 10.1016/j.vaccine.2004.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.04.009</ArticleId><ArticleId IdType="pubmed">15364436</ArticleId></ArticleIdList></Reference><Reference><Citation>Baril L., Dietemann J., Essevaz-Roulet M., Béniguel L., Coan P., Briles D.E., Guy B., Cozon G. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin. Exp. Immunol. 2006;145:277–286. doi: 10.1111/j.1365-2249.2006.03148.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03148.x</ArticleId><ArticleId IdType="pmc">PMC1809691</ArticleId><ArticleId IdType="pubmed">16879247</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari E., Negahdari B., Faraji F., Behdani M., Kazemi-Lomedasht F., Habibi-Anbouhi M. Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae. Biotechnol. Rep. 2019;24:e00385. doi: 10.1016/j.btre.2019.e00385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.btre.2019.e00385</ArticleId><ArticleId IdType="pmc">PMC6864353</ArticleId><ArticleId IdType="pubmed">31763198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gor D.O., Ding X., Briles D.E., Jacobs M.R., Greenspan N.S. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect. Immun. 2005;73:1304–1312. doi: 10.1128/IAI.73.3.1304-1312.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.3.1304-1312.2005</ArticleId><ArticleId IdType="pmc">PMC1064945</ArticleId><ArticleId IdType="pubmed">15731027</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., Schilling M., Ferguson L.M., Hollingshead S.K., Briles D.E., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine. 2000;18:1743–1754. doi: 10.1016/S0264-410X(99)00530-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(99)00530-7</ArticleId><ArticleId IdType="pubmed">10699322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bologa M., Kamtchoua T., Hopfer R., Sheng X., Hicks B., Bixler G., Hou V., Pehlic V., Yuan T., Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA–pneumococcal histidine triad protein D vaccine. Vaccine. 2012;30:7461–7468. doi: 10.1016/j.vaccine.2012.10.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.076</ArticleId><ArticleId IdType="pubmed">23123106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamtchoua T., Bologa M., Hopfer R., Neveu D., Hu B., Sheng X., Corde N., Pouzet C., Zimmermann G., Gurunathan S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013;31:327–333. doi: 10.1016/j.vaccine.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.11.005</ArticleId><ArticleId IdType="pubmed">23153437</ArticleId></ArticleIdList></Reference><Reference><Citation>Crain M.J., Waltman W.D., 2nd, Turner J.S., Yother J., Talkington D.F., McDaniel L.S., Gray B.M., Briles D.E. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun. 1990;58:3293–3299. doi: 10.1128/iai.58.10.3293-3299.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.58.10.3293-3299.1990</ArticleId><ArticleId IdType="pmc">PMC313652</ArticleId><ArticleId IdType="pubmed">1698178</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel L.S., Sheffield J.S., Delucchi P., Briles D.E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect. Immun. 1991;59:222–228. doi: 10.1128/iai.59.1.222-228.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.59.1.222-228.1991</ArticleId><ArticleId IdType="pmc">PMC257730</ArticleId><ArticleId IdType="pubmed">1987036</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsurahara T., Hotomi M., Yamauchi K., Billal D.S., Yamanaka N. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA) J. Infect. Chemother. 2008;14:393–398. doi: 10.1007/s10156-008-0647-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10156-008-0647-7</ArticleId><ArticleId IdType="pubmed">19089550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D.M., Darrieux M., Silva D.A., Leite L.C., Ferreira J.M., Jr., Ho P.L., Miyaji E.N., Oliveira M.L. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin. Vaccine Immunol. 2009;16:636–645. doi: 10.1128/CVI.00395-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00395-08</ArticleId><ArticleId IdType="pmc">PMC2681601</ArticleId><ArticleId IdType="pubmed">19279169</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo S.-U., Kim J.-J., Yang H., Kwon H.-J., Yang J.-Y., Iii R.C., Kweon M.-N. Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice. Vaccine. 2012;30:6816–6823. doi: 10.1016/j.vaccine.2012.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.015</ArticleId><ArticleId IdType="pubmed">23000127</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeela E.A., Burke Á., Neill D.R., Baxter C., Fernandes V.E., Ferreira D., Smeaton S., El-Rachkidy R., McLoughlin R.M., Mori A., et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog. 2010;6:e1001191. doi: 10.1371/journal.ppat.1001191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001191</ArticleId><ArticleId IdType="pmc">PMC2978728</ArticleId><ArticleId IdType="pubmed">21085613</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais V., Texeira E., Suarez N. Next-Generation Whole-Cell Pneumococcal Vaccine. Vaccines. 2019;7:151. doi: 10.3390/vaccines7040151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040151</ArticleId><ArticleId IdType="pmc">PMC6963273</ArticleId><ArticleId IdType="pubmed">31623286</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., Hansman D., Paton J.C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect. Immun. 1994;62:5683–5688. doi: 10.1128/iai.62.12.5683-5688.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.62.12.5683-5688.1994</ArticleId><ArticleId IdType="pmc">PMC303321</ArticleId><ArticleId IdType="pubmed">7960154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect. Immun. 2001;69:5997–6003. doi: 10.1128/IAI.69.10.5997-6003.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.10.5997-6003.2001</ArticleId><ArticleId IdType="pmc">PMC98727</ArticleId><ArticleId IdType="pubmed">11553536</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Suárez Mdel M., Cima-Cabal M.D., Flórez N., Garci P., Cernuda-Cernuda R., Astudillo A., Vázquez F., De Los Toyos J.R., Méndez F.J. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect. Immun. 2004;72:4534–4540. doi: 10.1128/IAI.72.8.4534-4540.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.8.4534-4540.2004</ArticleId><ArticleId IdType="pmc">PMC470670</ArticleId><ArticleId IdType="pubmed">15271913</ArticleId></ArticleIdList></Reference><Reference><Citation>Denoël P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine. 2011;29:5495–5501. doi: 10.1016/j.vaccine.2011.05.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.05.051</ArticleId><ArticleId IdType="pmc">PMC5061031</ArticleId><ArticleId IdType="pubmed">21624422</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund J., Vink P., Da Silva F.T., Lestrate P., Boutriau D. Safety, Immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clin. Vaccine Immunol. 2014;21:56–65. doi: 10.1128/CVI.00430-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00430-13</ArticleId><ArticleId IdType="pmc">PMC3910926</ArticleId><ArticleId IdType="pubmed">24173029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammitt L.L., Campbell J.C., Borys D., Weatherholtz R.C., Reid R., Goklish N., Moulton L.H., Traskine M., Song Y., Swinnen K., et al. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study. Vaccine. 2019;37:7482–7492. doi: 10.1016/j.vaccine.2019.09.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.076</ArticleId><ArticleId IdType="pubmed">31629570</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto A.T., Rosch J.W., Tuomanen E.I. Pneumolysin: Pathogenesis and Therapeutic Target. Front. Microbiol. 2020;11:1543. doi: 10.3389/fmicb.2020.01543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01543</ArticleId><ArticleId IdType="pmc">PMC7343714</ArticleId><ArticleId IdType="pubmed">32714314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>